455 E. MEDICAL CENTER BLVD, HOUSTON, TX
FibroBiologics Enters $1.2M Securities Purchase Agreement with Peak One
Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
FibroBiologics Enters Into Securities Purchase Agreement with Hamid Khoja
Appoints Leigh Steinberg to Board of Directors
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Appoints Kathleen 'Kate' Rubins, Ph.D. to Board of Directors
Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics, Inc. Approves 2026 Equity and Incentive Compensation Plan
Q2
Amended Annual Report
FY 2024
Q3
Q1
Effectiveness Notice
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence